{"id":673,"date":"2026-02-28T14:56:04","date_gmt":"2026-02-28T14:56:04","guid":{"rendered":"https:\/\/heartcareforyou.in\/blog\/cardiac-morbidity-definition-clinical-context-and-cardiology-overview\/"},"modified":"2026-02-28T14:56:04","modified_gmt":"2026-02-28T14:56:04","slug":"cardiac-morbidity-definition-clinical-context-and-cardiology-overview","status":"publish","type":"post","link":"https:\/\/heartcareforyou.in\/blog\/cardiac-morbidity-definition-clinical-context-and-cardiology-overview\/","title":{"rendered":"Cardiac Morbidity: Definition, Clinical Context, and Cardiology Overview"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\">Cardiac Morbidity Introduction (What it is)<\/h2>\n\n\n\n<p>Cardiac Morbidity means illness, complications, or reduced health related to the heart and circulation.<br\/>\nIt is a clinical outcome category rather than a single diagnosis.<br\/>\nIt is commonly discussed after events like myocardial infarction (heart attack), cardiac surgery, or during chronic disease follow-up.<br\/>\nIt is also used in research and quality improvement to describe non-fatal cardiovascular harms and their impact.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Why Cardiac Morbidity matters in cardiology (Clinical relevance)<\/h2>\n\n\n\n<p>Cardiac Morbidity matters because cardiology is not only about preventing death, but also about preventing disability, symptoms, hospitalizations, and long-term functional decline. Many cardiovascular conditions are survivable yet leave patients with persistent limitations, recurrent events, or treatment-related complications. Capturing these outcomes helps clinicians and health systems understand the real-world burden of cardiovascular disease.<\/p>\n\n\n\n<p>In clinical care, the concept supports clearer communication about risk. For example, two patients may have the same diagnosis (such as coronary artery disease), but very different morbidity profiles depending on ventricular function, arrhythmia burden, comorbidities, and prior procedures. Thinking in terms of morbidity encourages clinicians to look beyond a label and assess how the condition affects day-to-day physiology and function.<\/p>\n\n\n\n<p>In education and research, Cardiac Morbidity is a common endpoint in clinical trials, registries, and perioperative assessment. It is also used in quality metrics such as readmissions, complication rates, and procedure-related adverse events. These data can guide risk stratification, shared decision-making, and planning of follow-up intensity (varies by clinician and case).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Classification \/ types \/ variants<\/h2>\n\n\n\n<p>Cardiac Morbidity is not a single entity with universally fixed subtypes, but it is often categorized in practical ways depending on setting and purpose. Common classifications include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>By timing<\/strong><\/li>\n<li><strong>Acute cardiac morbidity:<\/strong> complications occurring over hours to days (for example, acute heart failure after myocardial infarction, peri-procedural myocardial injury, or new arrhythmias).<\/li>\n<li>\n<p><strong>Subacute or chronic cardiac morbidity:<\/strong> longer-term illness burden (for example, chronic heart failure symptoms, recurrent angina, or progressive valvular disease).<\/p>\n<\/li>\n<li>\n<p><strong>By clinical domain<\/strong><\/p>\n<\/li>\n<li><strong>Ischemic morbidity:<\/strong> angina, recurrent myocardial infarction, ischemia-driven hospitalizations, or need for revascularization (context-dependent).<\/li>\n<li><strong>Heart failure morbidity:<\/strong> congestion, reduced exercise tolerance, decompensation episodes, or repeat admissions.<\/li>\n<li><strong>Arrhythmic morbidity:<\/strong> symptomatic atrial fibrillation (AF), syncope, device therapies (such as implantable cardioverter-defibrillator shocks), or bradyarrhythmia requiring pacing.<\/li>\n<li><strong>Valvular morbidity:<\/strong> symptoms from stenosis\/regurgitation, heart failure related to valve disease, or complications after valve intervention.<\/li>\n<li>\n<p><strong>Thromboembolic morbidity:<\/strong> stroke\/systemic embolism related to AF or structural heart disease (often discussed as cardiovascular morbidity more broadly).<\/p>\n<\/li>\n<li>\n<p><strong>By cause<\/strong><\/p>\n<\/li>\n<li><strong>Disease-related morbidity:<\/strong> arising from the natural history of cardiovascular disease.<\/li>\n<li>\n<p><strong>Treatment-related morbidity:<\/strong> complications of medications (for example, bradycardia), devices (for example, lead issues), catheter procedures (for example, vascular complications), or surgery (for example, postoperative arrhythmias).<\/p>\n<\/li>\n<li>\n<p><strong>By measurement approach<\/strong><\/p>\n<\/li>\n<li><strong>Patient-centered morbidity:<\/strong> symptoms, functional class, quality of life, and activity limitations.<\/li>\n<li><strong>Event-based morbidity:<\/strong> hospitalizations, complications, repeat procedures, and clinically significant adverse events (definitions vary by protocol and patient factors).<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Relevant anatomy &amp; physiology<\/h2>\n\n\n\n<p>Understanding Cardiac Morbidity requires a working picture of how heart structure and circulation support oxygen delivery.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Chambers and pump function<\/strong><\/li>\n<li>The <strong>left ventricle (LV)<\/strong> generates systemic blood flow; LV dysfunction commonly leads to fatigue, dyspnea, and fluid retention.<\/li>\n<li>The <strong>right ventricle (RV)<\/strong> pumps to the lungs; RV failure can cause peripheral edema, hepatic congestion, and reduced LV filling.<\/li>\n<li>\n<p>The <strong>atria<\/strong> contribute to ventricular filling; atrial disease and atrial fibrillation can reduce cardiac output and raise thromboembolic risk.<\/p>\n<\/li>\n<li>\n<p><strong>Valves and flow<\/strong><\/p>\n<\/li>\n<li>The <strong>aortic and mitral valves<\/strong> strongly influence LV workload and forward flow.<\/li>\n<li>\n<p><strong>Stenosis<\/strong> increases pressure load; <strong>regurgitation<\/strong> increases volume load. Both can drive remodeling and heart failure morbidity.<\/p>\n<\/li>\n<li>\n<p><strong>Coronary circulation<\/strong><\/p>\n<\/li>\n<li>\n<p>The coronary arteries supply oxygen to myocardium. Reduced supply (atherosclerosis, spasm, thrombosis) can produce ischemia, infarction, arrhythmias, and contractile dysfunction.<\/p>\n<\/li>\n<li>\n<p><strong>Conduction system<\/strong><\/p>\n<\/li>\n<li>\n<p>The sinoatrial node, atrioventricular node, His\u2013Purkinje system, and ventricular myocardium coordinate rhythm. Disturbances can cause palpitations, syncope, heart failure worsening, or sudden hemodynamic compromise.<\/p>\n<\/li>\n<li>\n<p><strong>Vascular physiology and hemodynamics<\/strong><\/p>\n<\/li>\n<li><strong>Preload<\/strong> (venous return), <strong>afterload<\/strong> (arterial resistance), and <strong>contractility<\/strong> determine stroke volume.<\/li>\n<li>Neurohormonal systems (sympathetic nervous system, renin\u2013angiotensin\u2013aldosterone system) compensate in the short term but can worsen remodeling and chronic morbidity.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Pathophysiology or mechanism<\/h2>\n\n\n\n<p>Because Cardiac Morbidity is an umbrella concept, mechanisms vary by underlying disease and clinical context. Common pathways include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Myocardial ischemia and injury<\/strong><\/li>\n<li>Plaque rupture with thrombosis can occlude a coronary artery, causing myocardial infarction and subsequent scarring.<\/li>\n<li>\n<p>Even without complete occlusion, supply\u2013demand mismatch can cause ischemia, leading to chest discomfort, LV dysfunction, and arrhythmias.<\/p>\n<\/li>\n<li>\n<p><strong>Ventricular remodeling<\/strong><\/p>\n<\/li>\n<li>Injury (infarction, myocarditis) or chronic load (hypertension, valvular disease) can trigger hypertrophy, dilation, and fibrosis.<\/li>\n<li>\n<p>Remodeling changes compliance and contractility, increasing filling pressures and producing heart failure symptoms.<\/p>\n<\/li>\n<li>\n<p><strong>Hemodynamic overload<\/strong><\/p>\n<\/li>\n<li>Pressure overload (aortic stenosis, systemic hypertension) increases wall stress and hypertrophy.<\/li>\n<li>\n<p>Volume overload (mitral regurgitation, shunts) leads to chamber dilation and eventually reduced pump efficiency.<\/p>\n<\/li>\n<li>\n<p><strong>Electrical instability<\/strong><\/p>\n<\/li>\n<li>Fibrosis, ischemia, electrolyte disturbances, and ion channel abnormalities can produce atrial or ventricular arrhythmias.<\/li>\n<li>\n<p>Arrhythmias can cause symptoms directly and also reduce cardiac output, which can worsen heart failure morbidity.<\/p>\n<\/li>\n<li>\n<p><strong>Thrombosis and embolism<\/strong><\/p>\n<\/li>\n<li>Stasis (especially in AF), endothelial injury, and hypercoagulability increase thrombus formation risk.<\/li>\n<li>\n<p>Embolic events can cause neurologic morbidity; in cardiology contexts these outcomes are often tracked together as cardiovascular morbidity.<\/p>\n<\/li>\n<li>\n<p><strong>Iatrogenic (treatment-related) mechanisms<\/strong><\/p>\n<\/li>\n<li>Procedures can cause vascular injury, bleeding, myocardial injury, conduction disturbances, or inflammatory responses.<\/li>\n<li>Medications can cause hypotension, bradycardia, renal effects, or electrolyte changes that indirectly increase cardiac symptoms (varies by drug class and patient factors).<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Clinical presentation or indications<\/h2>\n\n\n\n<p>Cardiac Morbidity is encountered across many clinical scenarios. Typical presentations or contexts include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Recurrent <strong>chest pain<\/strong> or exertional angina limiting activity<\/li>\n<li><strong>Dyspnea<\/strong>, orthopnea, or edema suggesting heart failure decompensation<\/li>\n<li><strong>Palpitations<\/strong>, presyncope, or syncope suggesting arrhythmia-related morbidity<\/li>\n<li>Reduced exercise tolerance and fatigue after myocardial infarction or myocarditis<\/li>\n<li>Post-procedure complications (for example, access-site problems, new conduction abnormalities, pericardial symptoms)<\/li>\n<li>Frequent emergency visits or hospitalizations for cardiovascular symptoms<\/li>\n<li>New neurologic symptoms in a patient with atrial fibrillation (considering thromboembolic complications)<\/li>\n<li>Worsening renal function or hypotension complicating heart failure therapy (cardiorenal interactions; varies by case)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Diagnostic evaluation &amp; interpretation<\/h2>\n\n\n\n<p>Evaluating Cardiac Morbidity generally involves two parallel tasks: identifying the <strong>underlying cardiovascular diagnosis<\/strong> and measuring the <strong>severity and impact<\/strong> on function.<\/p>\n\n\n\n<p>Common components include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>History<\/strong><\/li>\n<li>Symptom pattern (exertional vs rest), triggers, duration, and associated features (dyspnea, diaphoresis, syncope).<\/li>\n<li>Prior cardiac events and procedures, medication tolerance, and adherence barriers (varies by patient factors).<\/li>\n<li>\n<p>Functional status: how symptoms affect daily activities, sleep, and work.<\/p>\n<\/li>\n<li>\n<p><strong>Physical examination<\/strong><\/p>\n<\/li>\n<li>Volume status (jugular venous pressure, edema, lung crackles).<\/li>\n<li>\n<p>Murmurs suggesting valvular disease; signs of poor perfusion (cool extremities, altered mentation in severe cases).<\/p>\n<\/li>\n<li>\n<p><strong>Electrocardiogram (ECG)<\/strong><\/p>\n<\/li>\n<li>\n<p>Rhythm diagnosis (AF, flutter, bradyarrhythmias), conduction delays, ischemic changes, or prior infarct patterns.<\/p>\n<\/li>\n<li>\n<p><strong>Laboratory testing<\/strong><\/p>\n<\/li>\n<li>Cardiac biomarkers (used when acute coronary syndrome is suspected).<\/li>\n<li>Natriuretic peptides (often used to support heart failure evaluation; interpretation depends on clinical context).<\/li>\n<li>\n<p>Electrolytes, kidney function, and thyroid testing when relevant to arrhythmias or medication effects.<\/p>\n<\/li>\n<li>\n<p><strong>Imaging<\/strong><\/p>\n<\/li>\n<li><strong>Transthoracic echocardiography (TTE):<\/strong> assesses ejection fraction, wall motion, chamber size, diastolic function, and valve disease.<\/li>\n<li><strong>Stress testing:<\/strong> evaluates inducible ischemia and functional capacity when appropriate.<\/li>\n<li><strong>Coronary imaging<\/strong> (computed tomography coronary angiography or invasive angiography): clarifies coronary anatomy in selected cases.<\/li>\n<li>\n<p><strong>Cardiac magnetic resonance (CMR):<\/strong> characterizes scar, inflammation, and cardiomyopathy patterns when needed.<\/p>\n<\/li>\n<li>\n<p><strong>Monitoring<\/strong><\/p>\n<\/li>\n<li>Ambulatory rhythm monitoring for intermittent symptoms.<\/li>\n<li>Device interrogation for patients with pacemakers or defibrillators.<\/li>\n<\/ul>\n\n\n\n<p>Interpretation is individualized: the same test abnormality can have different morbidity implications depending on symptoms, comorbidities, and reserve. Many institutions also use standardized definitions for complications and outcomes in registries or trials (definitions vary by protocol).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Management overview (General approach)<\/h2>\n\n\n\n<p>Management of Cardiac Morbidity is typically directed at the <strong>cause<\/strong>, the <strong>physiologic consequences<\/strong>, and the <strong>patient\u2019s functional impact<\/strong>. Approaches often overlap.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Conservative and lifestyle-focused measures<\/strong><\/li>\n<li>Education about disease mechanisms, symptom recognition, and risk factor modification is commonly part of care.<\/li>\n<li>\n<p>Cardiac rehabilitation may be used after events like myocardial infarction or revascularization to support functional recovery (availability and referral patterns vary).<\/p>\n<\/li>\n<li>\n<p><strong>Medical therapy<\/strong><\/p>\n<\/li>\n<li><strong>Anti-ischemic strategies<\/strong> (for example, agents that reduce myocardial oxygen demand) may reduce angina morbidity.<\/li>\n<li><strong>Heart failure therapies<\/strong> aim to reduce congestion, improve hemodynamics, and modify maladaptive neurohormonal activation (specific regimens vary by phenotype and guidelines).<\/li>\n<li><strong>Rate or rhythm control<\/strong> strategies for atrial fibrillation may reduce symptoms and improve functional status in selected patients.<\/li>\n<li>\n<p><strong>Antithrombotic therapy<\/strong> may reduce thromboembolic morbidity in appropriate contexts, balanced against bleeding risk.<\/p>\n<\/li>\n<li>\n<p><strong>Interventional cardiology<\/strong><\/p>\n<\/li>\n<li><strong>Percutaneous coronary intervention (PCI)<\/strong> may be used for acute coronary syndromes and selected stable ischemic disease scenarios to relieve ischemia or treat culprit lesions (indications vary by guideline and patient factors).<\/li>\n<li>\n<p>Catheter-based procedures for structural disease (for example, transcatheter valve interventions) can reduce morbidity from severe valvular disease in selected patients.<\/p>\n<\/li>\n<li>\n<p><strong>Electrophysiology procedures and devices<\/strong><\/p>\n<\/li>\n<li><strong>Catheter ablation<\/strong> may reduce arrhythmia burden and related symptoms for some arrhythmias.<\/li>\n<li><strong>Pacemakers<\/strong> address symptomatic bradycardia or conduction disease.<\/li>\n<li>\n<p><strong>Implantable cardioverter-defibrillators (ICDs)<\/strong> are used to reduce risk from malignant ventricular arrhythmias in selected populations; they can also contribute to morbidity through shocks or complications, so candidacy is individualized.<\/p>\n<\/li>\n<li>\n<p><strong>Cardiac surgery<\/strong><\/p>\n<\/li>\n<li>Coronary artery bypass grafting (CABG) and valve surgery can improve symptoms and outcomes in selected cases but carry perioperative morbidity risks that must be weighed.<\/li>\n<\/ul>\n\n\n\n<p>In practice, clinicians often combine these approaches, reassessing response over time and adjusting based on tolerance, comorbidities, and patient priorities (varies by clinician and case).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Complications, risks, or limitations<\/h2>\n\n\n\n<p>Because Cardiac Morbidity includes both disease burden and treatment-related harm, limitations are context-dependent. Common categories include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Disease progression<\/strong><\/li>\n<li>\n<p>Worsening heart failure, recurrent ischemia, progressive valve dysfunction, or increasing arrhythmia burden.<\/p>\n<\/li>\n<li>\n<p><strong>Acute decompensation<\/strong><\/p>\n<\/li>\n<li>\n<p>Episodes requiring emergency evaluation or hospitalization, including pulmonary edema, hypotension, or arrhythmic instability.<\/p>\n<\/li>\n<li>\n<p><strong>Thromboembolic and bleeding risks<\/strong><\/p>\n<\/li>\n<li>Thromboembolism may complicate atrial fibrillation or ventricular dysfunction.<\/li>\n<li>\n<p>Bleeding risk may rise with antithrombotic therapy; the balance is individualized.<\/p>\n<\/li>\n<li>\n<p><strong>Procedure-related complications<\/strong><\/p>\n<\/li>\n<li>\n<p>Vascular access complications, contrast-associated kidney injury, peri-procedural myocardial injury, stroke, infection, or conduction disturbances can occur depending on procedure type.<\/p>\n<\/li>\n<li>\n<p><strong>Medication limitations<\/strong><\/p>\n<\/li>\n<li>\n<p>Hypotension, bradycardia, kidney effects, electrolyte abnormalities, and drug\u2013drug interactions may limit therapy intensity (varies by patient factors).<\/p>\n<\/li>\n<li>\n<p><strong>Measurement limitations<\/strong><\/p>\n<\/li>\n<li>Morbidity definitions can differ across studies and hospitals, making comparisons imperfect.<\/li>\n<li>Patient-reported morbidity (symptoms, quality of life) may not track perfectly with imaging measures.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Prognosis &amp; follow-up considerations<\/h2>\n\n\n\n<p>Prognosis in Cardiac Morbidity depends on the underlying diagnosis, severity of physiologic impairment, response to therapy, and comorbid conditions. For example, reduced left ventricular systolic function, advanced valvular disease, recurrent ischemia, or frequent arrhythmias can increase the likelihood of future symptoms and hospitalizations. Coexisting conditions such as chronic kidney disease, diabetes, lung disease, or frailty may amplify morbidity burden.<\/p>\n\n\n\n<p>Follow-up typically focuses on:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Trajectory over time:<\/strong> stable, improving, or worsening symptoms and functional capacity.<\/li>\n<li><strong>Objective markers:<\/strong> imaging trends (ventricular function, valve gradients, chamber sizes), rhythm monitoring results, and laboratory patterns as clinically appropriate.<\/li>\n<li><strong>Therapy tolerance:<\/strong> side effects, blood pressure trends, renal function, and adherence barriers.<\/li>\n<li><strong>Rehabilitation and function:<\/strong> return of exercise capacity, work capability, and psychosocial recovery after major cardiac events.<\/li>\n<\/ul>\n\n\n\n<p>Some patients experience meaningful recovery, especially when the trigger is reversible or treated early. Others have persistent limitations due to scar, progressive remodeling, or recurrent events. The expected course often requires periodic reassessment and individualized planning (varies by clinician and case).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Cardiac Morbidity Common questions (FAQ)<\/h2>\n\n\n\n<p><strong>Q: What does Cardiac Morbidity mean in plain language?<\/strong><br\/>\nIt refers to illness or complications involving the heart that affect health and functioning. It can include symptoms, hospitalizations, and non-fatal events related to cardiovascular disease. It is broader than a single diagnosis.<\/p>\n\n\n\n<p><strong>Q: Is Cardiac Morbidity the same as mortality?<\/strong><br\/>\nNo. Mortality refers to death, while morbidity refers to illness burden and complications among people who are alive. In cardiology, both are tracked because a treatment might reduce symptoms or admissions even if it does not change survival, or vice versa.<\/p>\n\n\n\n<p><strong>Q: Does Cardiac Morbidity always mean a heart attack happened?<\/strong><br\/>\nNot necessarily. Cardiac Morbidity can result from heart failure, arrhythmias, valve disease, congenital conditions, or complications of procedures and medications. Myocardial infarction is one important cause, but not the only one.<\/p>\n\n\n\n<p><strong>Q: How do clinicians \u201cmeasure\u201d Cardiac Morbidity?<\/strong><br\/>\nMeasurement depends on the setting. It may involve counting clinical events (hospitalizations, recurrent ischemia, arrhythmia episodes), assessing function (exercise tolerance, symptom class), and using tests like echocardiography or ECGs. Research studies often use predefined composite endpoints, which can vary by protocol.<\/p>\n\n\n\n<p><strong>Q: What tests are commonly used when cardiac morbidity is suspected?<\/strong><br\/>\nClinicians often start with history, physical exam, and an ECG. Depending on symptoms, they may add blood tests, echocardiography, stress testing, coronary imaging, or rhythm monitoring. The selection depends on the suspected mechanism and urgency.<\/p>\n\n\n\n<p><strong>Q: Can someone have significant Cardiac Morbidity with a \u201cnormal\u201d ejection fraction?<\/strong><br\/>\nYes. Symptoms and complications can occur with preserved ejection fraction, such as in diastolic dysfunction (heart failure with preserved ejection fraction), valvular disease, ischemia without large infarction, or atrial fibrillation. Ejection fraction is informative but not a complete summary of cardiac health.<\/p>\n\n\n\n<p><strong>Q: What role do procedures and devices play in Cardiac Morbidity?<\/strong><br\/>\nProcedures and devices can reduce morbidity by relieving ischemia, correcting valve problems, or stabilizing dangerous rhythms. They can also add morbidity through complications, recovery time, or device-related issues. Whether the net effect is beneficial depends on patient factors and indication.<\/p>\n\n\n\n<p><strong>Q: How long does recovery take after a cardiac event that causes morbidity?<\/strong><br\/>\nRecovery timelines vary widely based on the event (for example, myocardial infarction versus decompensated heart failure), baseline function, and rehabilitation access. Some improvements occur over weeks, while remodeling and functional gains can evolve over months. Follow-up plans are individualized.<\/p>\n\n\n\n<p><strong>Q: What are typical next steps after Cardiac Morbidity is identified?<\/strong><br\/>\nNext steps usually include clarifying the underlying diagnosis, assessing severity, and selecting therapies aimed at the cause and symptom burden. Clinicians often also address risk factors and consider rehabilitation or monitoring strategies. The exact pathway varies by clinician and case.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cardiac Morbidity means illness, complications, or reduced health related to the heart and circulation. It is a clinical outcome category rather than a single diagnosis. It is commonly discussed after events like myocardial infarction (heart attack), cardiac surgery, or during chronic disease follow-up. It is also used in research and quality improvement to describe non-fatal cardiovascular harms and their impact.<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-673","post","type-post","status-publish","format-standard","hentry"],"_links":{"self":[{"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/posts\/673","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/comments?post=673"}],"version-history":[{"count":0,"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/posts\/673\/revisions"}],"wp:attachment":[{"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/media?parent=673"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/categories?post=673"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/tags?post=673"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}